A Comprehensive Survey on the Expediated Anti-COVID-19 Options Enabled by Metal Complexes—Tasks and Trials
Abstract
:1. Introduction
2. Metal Complexes in Medical Applications
3. Metal Complexes for Antiviral Applications
Nano-Based Metal Complexes
4. Metal Complexes and Anti-COVID-19 Applications
Mechanism of Anti-COVID-19 Activity of Metal Complexes
5. Challenges, Future Perspectives, and Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Santos-López, G.; Cortés-Hernández, P.; Vallejo-Ruiz, V.; Reyes-Leyva, J. SARS-CoV-2: Basic concepts, origin and treatment advances. Gac. Med. Mex. 2021, 157, 84–89. [Google Scholar] [CrossRef] [PubMed]
- Yang, D.; Leibowitz, J.L. The structure and functions of coronavirus genomic 3′ and 5′ ends. Virus Res. 2015, 206, 120–133. [Google Scholar] [CrossRef]
- Cui, J.; Li, F.; Shi, Z.-L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 2019, 17, 181–192. [Google Scholar] [CrossRef] [Green Version]
- Song, Z.; Xu, Y.; Bao, L.; Zhang, L.; Yu, P.; Qu, Y.; Zhu, H.; Zhao, W.; Han, Y.; Qin, C. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses 2019, 11, 59. [Google Scholar] [CrossRef] [Green Version]
- Chan, J.F.-W.; Kok, K.-H.; Zhu, Z.; Chu, H.; To, K.K.-W.; Yuan, S.; Yuen, K.-Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect. 2020, 9, 221–236. [Google Scholar] [CrossRef] [Green Version]
- Huang, J.; Song, W.; Huang, H.; Sun, Q. Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19. J. Clin. Med. 2020, 9, 1131. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, C.; Zhou, Q.; Li, Y.; Garner, L.V.; Watkins, S.P.; Carter, L.J.; Smoot, J.; Gregg, A.C.; Daniels, A.D.; Jervey, S.; et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent. Sci. 2020, 6, 315–331. [Google Scholar] [CrossRef] [PubMed]
- Gao, Y.; Yan, L.; Huang, Y.; Liu, F.; Zhao, Y.; Cao, L.; Wang, T.; Sun, Q.; Ming, Z.; Zhang, L.; et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 2020, 368, 779–782. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Romano, M.; Ruggiero, A.; Squeglia, F.; Maga, G.; Berisio, R. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping. Cells 2020, 9, 1267. [Google Scholar] [CrossRef] [PubMed]
- Wu, F.; Zhao, S.; Yu, B.; Chen, Y.-M.; Wang, W.; Song, Z.-G.; Hu, Y.; Tao, Z.-W.; Tian, J.-H.; Pei, Y.-Y.; et al. A new coronavirus associated with human respiratory disease in China. Nature 2020, 579, 265–269. [Google Scholar] [CrossRef] [Green Version]
- McDonald, S.M. RNA synthetic mechanisms employed by diverse families of RNA viruses. Wiley Interdiscip. Rev. RNA 2013, 4, 351–367. [Google Scholar] [CrossRef] [PubMed]
- Hillen, H.S.; Kokic, G.; Farnung, L.; Dienemann, C.; Tegunov, D.; Cramer, P. Structure of replicating SARS-CoV-2 polymerase. Nature 2020, 584, 154–156. [Google Scholar] [CrossRef] [PubMed]
- Artese, A.; Svicher, V.; Costa, G.; Salpini, R.; Di Maio, V.C.; Alkhatib, M.; Ambrosio, F.A.; Santoro, M.M.; Assaraf, Y.G.; Alcaro, S.; et al. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Drug Resist. Updat. 2020, 53, 100721. [Google Scholar] [CrossRef] [PubMed]
- FDA Approves First Treatment for COVID-19. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 (accessed on 24 June 2021).
- Naveed, M.; Uddin, S.; Khan, M.K.; Khan, Z. Remdesivir for the treatment of COVID-19: A need for combined in vivo and in vitro studies to evaluate the efficacy. J. Pharm. Pract. 2021, 34, 343–346. [Google Scholar] [CrossRef]
- European Medicines Agency. COVID-19: EMA Starts Rolling Review of Molnupiravir. 2021. Available online: https://www.ema.europa.eu/en/news/covid-19-ema-starts-rolling-review-molnupiravir (accessed on 24 November 2021).
- COVID-19 Vaccine Tracker. Available online: https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/ (accessed on 24 June 2021).
- COVID-19 First In Human Study to Evaluate Safety, Toler Ability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers. 2021. Available online: https://clinicaltrials.gov/ct2/show/NCT04392219?term=Molnupiravir&draw=2&rank=5 (accessed on 24 November 2021).
- Singh, A.; Singh, A.; Singh, R.; Misra, A. Molnupiravir in COVID-19: A systematic literature review. Diabetes Metab. Syndr. 2021, 15, 102329. [Google Scholar] [CrossRef]
- Taylor, M.W. Vaccines Against Viral Infections; Springer: Berlin/Heidelberg, Germany, 2014. [Google Scholar] [CrossRef]
- Ioannou, K.; Vlasiou, M.C. Metal-based complexes against SARS-CoV-2. Biometals 2022, 35, 639–652. [Google Scholar] [CrossRef]
- Cirri, D.; Pratesi, A.; Marzo, T.; Messori, L. Metallo therapeutics for COVID-19. Exploiting metal-based com pounds for the discovery of new antiviral drugs. Exp. Opin. Drug Discov. 2021, 16, 39–46. [Google Scholar] [CrossRef]
- De Paiva, R.E.F.; Neto, A.M.; Santos, I.A.; Jardim, A.C.G.; Corbi, P.P.; Bergamini, F.R.G. What is holding back the development of antiviral metallodrugs? A literature overview and implications for SARS-CoV-2 therapeutics and future viral outbreaks. Dalton Trans. 2020, 49, 16004–16033. [Google Scholar] [CrossRef]
- Karges, J.; Cohen, S.M. Metal complexes as antiviral agents for SARS-CoV-2. ChemBioChem 2021, 22, 2600–2607. [Google Scholar] [CrossRef]
- Rosenberg, B.; Vancamp, L.; Trosko, J.E.; Mansour, V.H. Platinum Compounds: A New Class of Potent Antitumour Agents. Nature 1969, 222, 385–386. [Google Scholar] [CrossRef]
- Orvig, C.; Abrams, M.J. Medicinal Inorganic Chemistry: Introduction. Chem. Rev. 1999, 99, 2201–2204. [Google Scholar] [CrossRef] [PubMed]
- Kovala-Demertzi, D.; Boccarelli, A.; Demertzis, M.; Coluccia, M. In vitroAntitumor Activity of 2-Acetyl Pyridine 4N-Ethyl Thiosemicarbazone and Its Platinum(II) and Palladium(II) Complexes. Chemotherapy 2007, 53, 148–152. [Google Scholar] [CrossRef] [PubMed]
- Sakurai, H.S.; Kojima, Y.; Yoshikawa, Y.; Kawabe, K.; Yasui, H. Antidiabetic vanadium(IV) and zinc(II) complexes. Coord. Chem. Rev. 2002, 226, 187–198. [Google Scholar] [CrossRef]
- Louie, A.Y.; Meade, T.J. Metal Complexes as Enzyme Inhibitors. Chem. Rev. 1999, 99, 2711–2734. [Google Scholar] [CrossRef]
- Kostova, I. Platinum Complexes as Anticancer Agents. Recent Patents Anti-Cancer Drug Discov. 2006, 1, 1–22. [Google Scholar] [CrossRef]
- Iakovidou, Z.; Papageorgiou, A.; Demertzis, A.M.; Mioglou, E.; Mourelatos, D.; Kotsis, A.; Yadav, P.N.; Kovala-Demertzi, D. Platinum(II) and palladium(II) complexes with 2-acetylpyridine thiosemicarbazone: Cytogenetic and antineoplastic effects. Anti-Cancer Drugs 2001, 12, 65–70. [Google Scholar] [CrossRef]
- Huang, R.; Wallqvist, A.; Covell, D.G. Anticancer metal compounds in NCI’s tumor-screening database: Putative mode of action. Biochem. Pharmacol. 2005, 69, 1009–1039. [Google Scholar] [CrossRef] [PubMed]
- Galanski, M.; Jakupec, M.; Keppler, B. Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches. Curr. Med. Chem. 2005, 12, 2075–2094. [Google Scholar] [CrossRef]
- Gielen, M.; Tiekink, E.R.T. Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: The Use of Metals in Medicine; Wiley: Hoboken, NJ, USA, 2005. [Google Scholar]
- Karki, S.S.; Thota, S.; Darj, S.Y.; Balzarini, J.; De Clercq, E. Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds. Bioorg. Med. Chem. 2007, 15, 6632–6641. [Google Scholar] [CrossRef]
- Deegan, C.; Coyle, B.; McCann, M.; Devereux, M.; Egan, D.A. In vitro anti-tumour effect of 1,10-phenanthroline-5,6-dione (phendione), [Cu(phendione)3](ClO4)2·4H2O and [Ag(phendione)2]ClO4 using human epithelial cell lines. Chem. Interact. 2006, 164, 115–125. [Google Scholar] [CrossRef] [Green Version]
- Afrasiabi, Z.; Sinn, E.; Chen, J.; Ma, Y.; Rheingold, A.L.; Zakharov, L.N.; Rath, N.; Padhye, S. Appended 1,2-naphthoquinones as anticancer agents 1: Synthesis, structural, spectral and antitumor activities of ortho-naphthaquinone thiosemicarbazone and its transition metal complexes. Inorg. Chim. Acta 2004, 357, 271–278. [Google Scholar] [CrossRef]
- Alderden, R.A.; Hall, M.D.; Hambley, T. The Discovery and Development of Cisplatin. J. Chem. Educ. 2006, 83, 728–734. [Google Scholar] [CrossRef]
- Gomez, A.; Quiroga, C. Navarro Ranninger, Contribution to the SAR field of metallated and coordination complexes. Coord. Chem. Rev. 2004, 248, 119. [Google Scholar]
- Nath Yadav, P.; Demertzis, M.A.; Kovala-Demertzi, D.; Skoulika, S.; West, D.X. Palladium(II) Complex of the 5-Hydroxypyridine-2-carbaldehyde N(4)-ethylthiosemicarbazone: Synthesis and Characterization. Inorg. Chim. Acta 2003, 349, 30. [Google Scholar]
- Wong, E.; Giandomenico, C.M. Current Status of Platinum-Based Antitumor Drugs. Chem. Rev. 1999, 99, 2451–2466. [Google Scholar] [CrossRef]
- Hambley, T.W. The influence of structure on the activity and toxicity of Pt anti-cancer drugs. Coord. Chem. Rev. 1997, 166, 181–223. [Google Scholar] [CrossRef]
- Stordal, B.; Pavlakis, N.; Davey, R. Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review. Cancer Treat. Rev. 2007, 33, 347–357. [Google Scholar] [CrossRef] [Green Version]
- Gojo, I.; Tidwell, M.L.; Greer, J.; Takebe, N.; Seiter, K.; Pochron, M.F.; Johnson, B.; Sznol, M.; Karp, J.E. Phase I and pharmacokinetic study of Triapine®, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk. Res. 2007, 31, 1165–1173. [Google Scholar] [CrossRef]
- Quiroga, A.G.; Perez, J.M.; Lopez-Solera, I.; Montero, E.I.; Masaguer, J.R.; Alonso, C.; Navarro-Ranninger, C. Binuclear chlo-ro-bridged palladated and platinated complexes derived from p-isopropylbenzaldehyde thiosemicarbazone with cytotoxicity against cisplatin resistant tumor cell lines. J. Inorg. Biochem. 1998, 69, 275–281. [Google Scholar] [CrossRef]
- Rosu, T.; Pahontu, E.; Pasculescu, S.; Georgescu, R.; Stanica, N.; Curaj, A.; Popescu, A.; Leabu, M. Synthesis, characterization antibacterial and antiproliferative activity of novel Cu(II) and Pd(II) complexes with 2-hydroxy-8-R-tricyclo[7.3.1.0.2,7]tridecane-13-one thiosemicarbazone. Eur. J. Med. Chem. 2010, 45, 1627–1634. [Google Scholar] [CrossRef]
- Kovala-Demertzi, D.; Demertzis, M.A.; Filiou, E.; Pantazaki, A.A.; Yadav, P.N.; Miller, J.R.; Zheng, Y.; Kyriakidis, D.A. Platinum(II) and palladium(II) complexes with 2-acetyl pyridine 4N-ethyl thiosemicarbazone able to overcome the cis-platin resistance. Structure, antibacterial activity and DNA strand breakage. Biometals 2003, 16, 411–418. [Google Scholar] [CrossRef]
- Đilović, I.; Rubčić, M.; Vrdoljak, V.; Pavelić, S.K.; Kralj, M.; Piantanida, I.; Cindrić, M. Novel thiosemicarbazone derivatives as potential antitumor agents: Synthesis, physicochemical and structural properties, DNA interactions and antiproliferative activity. Bioorg. Med. Chem. 2008, 16, 5189–5198. [Google Scholar] [CrossRef] [PubMed]
- Finch, A.R.; Liu, M.-C.; Grill, S.P.; Rose, W.C.; Loomis, R.; Vasquez, K.M.; Cheng, Y.-C.; Sartorelli, A.C. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol. 2000, 59, 983–991. [Google Scholar] [CrossRef] [PubMed]
- Domagk, G.; Behnisch, R.; Mietzsch, F.; Schmidt, H. On a new class of compounds effective in vitro against tubercle bacilli. Naturwissenschaften 1946, 56, 315. [Google Scholar] [CrossRef]
- Kasuga, N.C.; Sekino, K.; Ishikawa, M.; Honda, A.; Yokoyama, M.; Nakano, S.; Shimada, N.; Koumo, C.; Nomiya, K. Synthesis, structural characterization and antimicrobial activities of 12 zinc(II) complexes with four thiosemicarbazone and two semi-carbazone ligands. J. Inorg. Biochem. 2003, 96, 298–310. [Google Scholar] [CrossRef] [PubMed]
- Feun, L.; Modiano, M.; Lee, K.; Mao, J.; Marini, A.; Savaraj, N.; Plezia, P.; Almassian, B.; Colacino, E.; Fischer, J.; et al. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother. Pharmacol. 2002, 50, 223–229. [Google Scholar] [CrossRef] [PubMed]
- Bharti, N.; Husain, K.; Garza, M.G.; Cruz-Vega, E.D.; Castro-Garza, J.; Mata-Cardenas, B.D.; Naqvi, F.; Azam, A. Synthesis and in vitro antiprotozoal activity of 5-nitrothiophene-2-carboxaldehyde thiosemicarbazone derivatives. Bioorg. Med. Chem. Lett. 2002, 12, 3475–3478. [Google Scholar] [CrossRef]
- De Oliveira, R.B.; De Souza-Fagundes, E.M.; Soares, R.P.; Andrade, A.; Krettli, A.U.; Zani, C.L. Synthesis and antimalarial activity of semicarbazone and thiosemicarbazone derivatives. Eur. J. Med. Chem. 2008, 43, 1983–1988. [Google Scholar] [CrossRef]
- Abid, M.; Agarwal, S.M.; Azam, A. Synthesis and antiamoebic activity of metronidazole thiosemicarbazone analogues. Eur. J. Med. Chem. 2008, 43, 2035–2039. [Google Scholar] [CrossRef]
- Quenelle, D.C.; Keith, K.A.; Kern, E.R. In vitro and in vivo evaluation of isatin-beta-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. Antivir. Res. 2006, 71, 24e30. [Google Scholar] [CrossRef]
- Vieites, M.L.; Otero, D.; Santos, J.; Toloza, R.; Figueroa, E.; Normbuena, C.; Olea Azar, G.; Aguirre, H.; Cerecetto, M.; Gonzalez, A.; et al. Gambino, Platinum(II) metal complexes as potential anti-Trypanosoma cruzi agents. J. Inorg. Biochem. 2008, 102, 1033–1043. [Google Scholar] [CrossRef] [PubMed]
- Yogeeswari, P.; Sriram, D.; Jit, L.R.J.S.; Kumar, S.S.; Stables, J.P. Anticonvulsant and neurotoxicity evaluation of some 6-chlorobenzothiazolyl-2-thiosemicarbazones. Eur. J. Med. Chem. 2002, 37, 231–236. [Google Scholar] [CrossRef] [PubMed]
- Vieites, M.; Otero, L.; Santos, D.; Olea-Azar, C.; Norambuena, E.; Aguirre, G.; Cerecetto, H.; González, M.; Kemmerling, U.; Morello, A.; et al. Platinum-based complexes of bioactive 3-(5-nitrofuryl)acroleine thiosemicarbazones showing anti-Trypanosoma cruzi activity. J. Inorg. Biochem. 2009, 103, 411–418. [Google Scholar] [CrossRef]
- Sodhi, R.K. Metal Complexes in Medicine: An Overview and Update from Drug Design Perspective. Cancer Ther. Oncol. Int. J. 2019, 14, 1–8. [Google Scholar] [CrossRef]
- Karaküçük-İyidoğan, A.; Taşdemir, D.; Oruç-Emre, E.E.; Balzarini, J. Novel platinum(II) and palla-dium(II) complexes of thiosemicarbazones derived from 5-substitutedthiophene-2-carboxaldehydes and their antiviral and cytotoxic activities. Eur. J. Med. Chem. 2011, 46, 5616–5624. [Google Scholar] [CrossRef]
- Diaz, R.S.; Shytaj, I.L.; Giron, L.B.; Obermaier, B.; Della Libera, E.; Galinskas, J.; Dias, D.; Hunter, J.; Janini, M.; Gossen, G.; et al. Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial. Int. J. Antimicrobial. Agents 2019, 54, 592–600. [Google Scholar] [CrossRef]
- Savarino, A.; Shytaj, I.L. Chloroquine and beyond: Explor ing antirheumatic drugs to reduce immune hyperactivation in HIV/AIDS. Retrovirology 2015, 12, 51. [Google Scholar] [CrossRef] [Green Version]
- Blindauer, C.A.; Sigel, A.; Operschall, B.P.; Griesser, R.; Holy, A.; Sigel, A. Extent of Intramolecular π-stacks in Aqueous Solution in Mixed-Ligand Copper(II) Complexes Formed by Heteroaromatic Amines and the Anticancer and Antivirally Active 9-[2-(Phosphonomethoxy)Ethyl]Guanine (Pmeg). A Comparison with Related Acyclic Nucleotide Analogues. Polyhedron 2016, 103, 248–260. [Google Scholar]
- Nourian, A.; Khalili, H. Sofosbuvir as a potential option for the treatment of COVID-19. Acta Biomed. 2020, 91, 239–241. [Google Scholar]
- Carcelli, M.; Fisicaro, E.; Compari, C.; Contardi, L.; Rogolino, D.; Solinas, C.; Stevaert, A.; Naesens, L. Antiviral activity and metal ion-binding properties of some 2-hydroxy-3-methoxyphenyl acylhydrazones. Biometals 2017, 31, 81–89. [Google Scholar] [CrossRef]
- Nagaj, J.; Starosta, R.; Jezowska-Bojczuk, M. Acid–base characterization, coordination properties towards copper(II) ions and DNA interaction studies of ribavirin, an antiviral drug. J. Inorg. Biochem. 2015, 142, 68–74. [Google Scholar] [CrossRef] [PubMed]
- Kirin, V.P.; Demkin, A.G.; Sukhikh, T.S.; Ilyicheva, T.N.; Maksakov, V.A. Cobalt complexes with biguanide deriva-tives—Synthesis, structure and antiviral activity. J. Mol. Struct. 2022, 1250, 131486. [Google Scholar] [CrossRef]
- Wanga, C.; Zhanga, R.; Weia, X.; Lva, M.; Jiang, Z. Metalloimmunology: The metal ion-controlled immunity. Adv. Immunol. 2020, 145, 187–241. [Google Scholar]
- Reed, S.G.; Orr, M.T.; Fox, C.B. Key roles of adjuvants in modern vaccines. Nat. Med. 2013, 19, 1597–1608. [Google Scholar] [CrossRef]
- Mohamed, G.G.; El-Sherif, A.A.; Saad, M.A.; El-Sawy, S.E.; Morgan, S.M. Mixed-ligand complex formation of tenoxicam drug with some transition metal ions in presence of valine: Synthesis, characterization, molecular docking, potentiometric and evaluation of the humeral immune response of calves. J. Mol. Liq. 2016, 223, 1311–1332. [Google Scholar] [CrossRef]
- El-Sonbati, A.; Diab, M.; Mohamed, G.; Saad, M.; Morgan, S.; El-Sawy, S. Polymer complexes. LXXVII. Synthesis, characterization, spectroscopic studies and immune response in cattle of quinoline polymer complexes. Appl. Organomet. Chem. 2019, 33, e4973. [Google Scholar] [CrossRef]
- Behzadi, M.; Vakili, B.; Ebrahiminezhad, A.; Nezafat, N. Iron nanoparticles as novel vaccine adjuvants. Eur. J. Pharm. Sci. 2021, 159, 105718. [Google Scholar] [CrossRef]
- Dykman, L.A. Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases. Expert Rev. Vaccines 2020, 19, 465–477. [Google Scholar] [CrossRef] [Green Version]
- Dykman, L.A.; Khlebtsov, N.G. Immunological properties of gold nanoparticles. Chem. Sci. 2021, 8, 1719–1735. [Google Scholar] [CrossRef] [Green Version]
- Li, Y.; Jin, Q.; Ding, P.; Zhou, W.; Chai, Y.; Li, X.; Wang, Y.; Zhang, G.-P. Gold nanoparticles enhance immune responses in mice against recombinant classical swine fever virus E2 protein. Biotechnol. Lett. 2020, 42, 1169–1180. [Google Scholar] [CrossRef]
- Neto, L.M.M.; Kipnis, A.; Junqueira-Kipnis, A.P. Role of Metallic Nanoparticles in Vaccinology: Implications for Infectious Disease Vaccine Development. Front. Immunol. 2017, 8, 239. [Google Scholar] [CrossRef] [Green Version]
- Sengupta, A.; Azharuddin, M.; Al-Otaibi, N.; Hinkula, J. Efficacy and Immune Response Elicited by Gold Nanoparticle- Based Nanovaccines against Infectious Diseases. Vaccines 2022, 10, 505. [Google Scholar] [CrossRef] [PubMed]
- Teng, Z.; Sun, S.; Chen, H.; Huang, J.; Du, P.; Dong, H.; Xu, X.; Mu, S.; Zhang, Z.; Guo, H. Golden-star nanoparticles as ad-juvant effectively promotes immune response to foot-and-mouth disease virus-like particles vaccine. Vaccines 2018, 36, 6752–6760. [Google Scholar] [CrossRef]
- Esquezaro, P.G.; Manzano, C.M.; Nakahata, D.H.; Santos, I.A.; Ruiz, U.E.; Santiago, M.B.; Silva, N.B.; Martins, C.H.; Pereira, D.H.; Bergamini, F.R.G.; et al. Synthesis, spectroscopic characterization and in vitro antibacterial and antiviral activities of novel silver(I) complexes with mafenide and ethyl-mafenide. J. Mol. Struct. 2021, 1246, 131261. [Google Scholar] [CrossRef]
- Maldonado, N.; Amo-Ochoa, P. The role of coordination compounds in virus research. Different approaches and trends. Dalton Trans. 2021, 50, 2310–2323. [Google Scholar] [CrossRef]
- Zoppi, C.; Messori, L.; Pratesi, A. ESI MS studies highlight the selective interaction of Auranofin with protein free thiols. Dalton Trans. 2020, 49, 5906–5913. [Google Scholar] [CrossRef]
- Kowalczyk, M.; Golonko, A.; Swisłocka, R.; Kalinowska, M.; Parcheta, M.; Swiergiel, A.; Lewandowski, W. Drug Design Strategies’ for the Treatment of Viral Disease. Plant Phenolic Compounds and Their Derivatives. Front. Pharmacol. 2021, 12, 709104. [Google Scholar] [CrossRef]
- Pettinari, C.; Pettinari, R.; Di Nicola, C.; Tombesi, A.; Scuri, S.; Marchetti, F. Antimicrobial MOFs. Coord. Chem. Rev. 2021, 446, 214121. [Google Scholar] [CrossRef]
- Niikura, K.; Matsunaga, T.; Suzuki, T.; Kobayashi, S.; Yamaguchi, H.; Orba, Y.; Kawaguchi, A.; Hasegawa, H.; Kajino, K.; Ninomiya, T.; et al. Gold Nanoparticles as a Vaccine Platform: Influence of Size and Shape on Immunological Responses in Vitro and in Vivo. ACS Nano 2013, 7, 3926–3938. [Google Scholar] [CrossRef]
- Staroverov, S.A.; Vidyasheva, I.V.; Gabalov, K.P.; Vasilenko, O.A.; Laskavyi, V.N.; Dykman, L.A. Immunostimulatory Effect of Gold Nanoparticles Conjugated with Transmissible Gastroenteritis Virus. Immunol. Microbiol. 2011, 151, 1350–1358. [Google Scholar] [CrossRef]
- Farfán-Castro, S.; García-Soto, M.J.; Comas-García, M.; Arévalo-Villalobos, J.-I.; Palestino, G.; González-Ortega, O.; Rosales Mendoza, S. Synthesis and immunogenicity assessment of a gold nanoparticle conjugate for the delivery of a peptide from SARS-CoV-2. Nanomedicine 2021, 34, 102372. [Google Scholar] [CrossRef]
- Sekimukai, H.; Iwata-Yoshikawa, N.; Fukushi, S.; Tani, H.; Kataoka, M.; Suzuki, T.; Hasegawa, H.; Niikura, K.; Arai, K.; Nagata, N. Gold nanoparticle-adiuvanted S protein induces a strong antigen-specific-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs. Microbiol. Immunol. 2020, 64, 33–51. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Garrido, C.; Simpson, A.C.; Dahl, N.P.; Bresee, J.; Whitehead, D.C.; Lindsey, A.E.; Harris, T.L.; Smith, C.A.; Carter, C.J.; Feldheim, D.L.; et al. Gold nanoparticles to improve HIV drug delivery. Futur. Med. Chem. 2015, 7, 1097–1107. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.-S.; Hung, Y.-C.; Lin, W.-H.; Huang, G.S. Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. Nanotechnology 2010, 21, 195101. [Google Scholar] [CrossRef] [Green Version]
- Zazo, H.; Colino, C.I.; Warzecha, K.T.; Hoss, M.; Gbureck, U.; Trautwein, C.; Tacke, F.; Lanao, J.M.; Bartneck, M. Gold Nanocarriers for Macrophage-Targeted Therapy of Human Immunodeficiency Virus. Macromol. Biosci. 2016, 17, 1600359. [Google Scholar] [CrossRef]
- Paul, A.M.; Shi, Y.; Acharya, D.; Douglas, J.R.; Cooley, A.; Anderson, J.F.; Huang, F.; Bai, F. Delivery of antiviral small inter-fering RNA with gold nanoparticles inhibits dengue virus infection in vitro. J. Gen. Virol. 2014, 95, 1712–1722. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Horcajada, P.; Chalati, T.; Serre, C.; Gillet, B.; Sébrié, C.; Baati, T.; Eubank, J.F.; Heurtaux, D.; Clayette, P.; Kreuz, C.; et al. Porous metal–organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat. Mater. 2009, 9, 172–178. [Google Scholar] [CrossRef]
- Yan, W.; Jain, A.; O’Carra, R.; Woodward, J.G.; Li, W.; Li, G.; Nath, A.; Mumper, R.J. Lipid nanoparticles with accessible nickel as a vaccine delivery system for single and multiple his-tagged HIV antigens. Res. Palliat. Care 2009, 1, 1–11. [Google Scholar]
- Zachar, O. Nanomedicine formulations for respiratory infections by inhalation delivery: Covid-19 and beyond. Med. Hypotheses 2022, 159, 110753. [Google Scholar] [CrossRef]
- Roome, T.; Razzak, A. Clinical implications of metals-based drug-delivery systems. In Metal Nanoparticles for Drug Delivery and Diagnostic Applications; Elsevier: Amsterdam, The Netherlands, 2020; pp. 237–258. [Google Scholar]
- Maduray, K.; Parboosing, R. Metal Nanoparticles: A Promising Treatment for Viral and Arboviral Infections. Biol. Trace Element Res. 2020, 199, 3159–3176. [Google Scholar] [CrossRef]
- Tortella, G.; Rubilar, O.; Fincheira, P.; Pieretti, J.; Duran, P.; Lourenço, I.; Seabra, A. Bactericidal and Virucidal Activities of Biogenic Metal-Based Nanoparticles: Advances and Perspectives. Antibiotics 2021, 10, 783. [Google Scholar] [CrossRef] [PubMed]
- Rai, M.; Ingle, A.P.; Gupta, I.; Brandelli, A. Bioactivity of noble metal nanoparticles decorated with biopolymers and their application in drug delivery. Int. J. Pharm. 2015, 496, 159–172. [Google Scholar] [CrossRef]
- Yang, J.; Yue, L.; Yang, Z.; Miao, Y.; Ouyang, R.; Hu, Y. Metal-Based Nanomaterials: Work as Drugs and Carriers against Viral Infections. Nanomaterials 2021, 11, 2129. [Google Scholar] [CrossRef]
- Bibi, S.; Urrehman, S.; Khalid, L.; Yaseen, M.; Khan, A.Q.; Jia, R. Metal doped fullerene complexes as promising drug delivery materials against COVID-19. Chem. Pap. 2021, 75, 6487–6497. [Google Scholar] [CrossRef]
- Fischer, N.O.; Blanchette, C.D.; Chromy, B.A.; Kuhn, E.A.; Segelke, B.W.; Corzett, M.; Bench, G.; Mason, P.W.; Hoeprich, P.D. Immobilization of His-Tagged Proteins on Nickel-Chelating Nanolipoprotein Particles. Bioconjugate Chem. 2009, 20, 460–465. [Google Scholar] [CrossRef] [PubMed]
- Halimi, V.; Daci, A.; Stojanovska, S.; Panovska-Stavridis, I.; Stevanovic, M.; Filipce, V.; Grozdanova, A. Current regulatory approaches for accessing potential COVID-19 therapies. J. Pharm. Policy Pract. 2020, 13, 1–4. [Google Scholar] [CrossRef] [PubMed]
- Naureen, B.; Miana, G.; Shahid, K.; Asghar, M.; Tanveer, S.; Sarwar, A. Iron (III) and zinc (II) monodentate Schiff base metal complexes: Synthesis, characterisation and biological activities. J. Mol. Struct. 2021, 1231, 129946. [Google Scholar] [CrossRef]
- Tripathi, K. A review–can metal ions be incorporated into drugs? Asian J. Res. Chem. 2009, 2, 14–18. [Google Scholar]
- Vlasiou, M.C.; Pafti, K.S. Screening possible drug molecules for Covid-19. The example of vanadium (III/IV/V) complex molecules with computational chemistry and molecular docking. Comput. Toxicol. 2021, 18, 100157. [Google Scholar] [CrossRef]
- Ali, A.; Sepay, N.; Afzal, M.; Alarifi, A.; Shahid, M.; Ahmad, M. Molecular designing, crystal structure determination and in silico screening of copper(II) complexes bearing 8-hydroxyquinoline derivatives as anti-COVID-19. Bioorg. Chem. 2021, 110, 104772. [Google Scholar] [CrossRef]
- Almalki, S.A.; Bawazeer, T.M.; Asghar, B.; Alharbi, A.; Aljohani, M.M.; Khalifa, M.E.; El-Metwaly, N. Synthesis and characterization of new thiazole-based Co (II) and Cu (II) complexes; therapeutic function of thiazole towards COVID-19 in comparing to current antivirals in treatment protocol. J. Mol. Struct. 2021, 2021, 130961. [Google Scholar] [CrossRef] [PubMed]
- Refat, M.S.; Gaber, A.; Alsanie, W.F. Utilization and simulation of innovative new binuclear Co (ii), Ni (ii), Cu (ii), and Zn (ii) diimine Schiff base complexes in sterilization and coronavirus resistance (Covid-19). Open Chem. 2021, 19, 772–784. [Google Scholar] [CrossRef]
- Rad, A.S.; Ardjmand, M.; Esfahani, M.R.; Khodashenas, B. DFT calculations towards the geometry optimization, electronic structure, infrared spectroscopy and UV–vis analyses of Favipiravir adsorption on the first-row transition metals doped fullerenes; a new strategy for COVID-19 therapy. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2021, 247, 119082. [Google Scholar] [CrossRef] [PubMed]
- Refat, M.S.; Altalhi, T.; Bakare, S.B.; Al-Hazmi, G.H.; Alam, K. New Cr(III), Mn(II), Fe(III), Co(II), Ni(II), Zn(II), Cd(II), and Hg(II) Gibberellate Complexes: Synthesis, Structure, and Inhibitory Activity Against COVID-19 Protease. Russ. J. Gen. Chem. 2021, 91, 890–896. [Google Scholar] [CrossRef] [PubMed]
- Mohamed, G.G.; Omar, M.M.; Ahmed, Y.M. Metal complexes of tridentate schiff base: Synthesis, characterization, biological activity and molecular docking studies with COVID-19 protein receptor. J. Inorg. Gen. Chem. 2021, 647, 2201–2218. [Google Scholar] [CrossRef] [PubMed]
- Hecel, A.; Ostrowska, M.; Stokowa-Sołtys, K.; Wątły, J.; Dudek, D.; Miller, A.; Potocki, S.; Matera-Witkiewicz, A.; Dominguez-Martin, A.; Kozłowski, H.; et al. Zinc (II)—The overlooked éminence grise of chloroquine’s fight against COVID-19? Pharmaceuticals 2020, 13, 228. [Google Scholar] [CrossRef] [PubMed]
- Poupaert, J.H.; Aguida, B.; Hountondji, C. Study of the interaction of zinc cation with azithromycin and its significance in the COVID-19 treatment: A molecular approach. Open Biochem. J. 2020, 14, 33–40. [Google Scholar] [CrossRef]
- Marzo, T.; Messori, L. (A role for metal-based drugs in fghting COVID-19 infection? The case of auranofn. ACS Med. Chem. Lett. 2020, 11, 1067–1068. [Google Scholar] [CrossRef]
- Rothan, H.A.; Stone, S.; Natekar, J.; Kumari, P.; Arora, K.; Kumar, M. The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells. Virology 2020, 547, 7–11. [Google Scholar] [CrossRef]
- Gil-Moles, M.; Basu, U.; Büssing, R.; Hofmeister, H.; Türck, S.; Varchmin, A.; Ott, I. Gold metallodrugs to target coronavirus proteins: Inhibitory effects on the spike-ACE2 interaction and PLpro protease activity by auranofn and gold organometallics. Chem 2020, 26, 15140–15144. [Google Scholar] [CrossRef]
- Yang, N.; Tanner, J.A.; Zheng, B.-J.; Watt, R.M.; He, M.-L.; Lu, L.-Y.; Jiang, J.-Q.; Shum, K.-T.; Lin, Y.-P.; Wong, K.-L.; et al. Bismuth complexes inhibit the SARS coronavirus. Angew. Chem. Int. Ed. 2007, 46, 6464–6468. [Google Scholar] [CrossRef] [PubMed]
- Yuan, S.; Wang, R.; Chan, J.F.-W.; Zhang, A.J.; Cheng, T.; Chik, K.K.-H.; Ye, Z.-W.; Wang, S.; Lee, A.C.-Y.; Jin, L.; et al. Metallodrug ranitidine bismuth cit rate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nat. Microbiol. 2020, 11, 1439–1448. [Google Scholar] [CrossRef] [PubMed]
- Frick, D.N. Helicases as antiviral drug targets. Drug News Perspect. 2003, 16, 355–362. [Google Scholar] [CrossRef] [PubMed]
- Wolf, D.C.; Wolf, C.H.; Rubin, D.T. Temporal Improvement of a COVID-19-Positive Crohn’s Disease Patient Treated With Bismuth Subsalicylate. Am. J. Gastroenterol. 2020, 115, 1298. [Google Scholar] [CrossRef] [PubMed]
- Boros, E.; Dyson, P.J.; Gasser, G. Classification of metal-based drugs according to their mechanisms of action. Chem 2020, 6, 41–60. [Google Scholar] [CrossRef]
- Riccardi, L.; Genna, V.; De Vivo, M. Metal–ligand interactions in drug design. Nat. Rev. Chem. 2018, 2, 100–112. [Google Scholar] [CrossRef]
- Fuertes, M.A.; Castilla, J.; Alonso, C.; Pérez, J.M. Cisplatin biochemical mechanism of action: From cytotoxic ity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr. Med. Chem. 2003, 10, 257–266. [Google Scholar] [CrossRef]
- Harbut, M.B.; Vilchèze, C.; Luo, X.; Hensler, M.E.; Guo, H.; Yang, B.; Chatterjee, A.K.; Nizet, V.; Jacobs, W.R.; Schultz, P.G.; et al. Auranofn exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc. Natl. Acad. Sci. USA 2015, 112, 4453–4458. [Google Scholar] [CrossRef] [Green Version]
- Roder, C.; Thomson, M.J. Auranofin: Repurposing an Old Drug for a Golden New Age. Drugs R&D 2015, 15, 13–20. [Google Scholar] [CrossRef] [Green Version]
- Walz, D.T.; DiMartino, M.J.; Griswold, D.E.; Intoccia, A.P.; Flanagan, T.L. Biologic actions and pharmacokinetic studies of auranofn. Am. J. Med. 1983, 75, 90–108. [Google Scholar] [CrossRef]
- Fung, T.S.; Liu, D.X. Coronavirus infection, ER stress, apoptosis and innate immunity. Front. Microbiol. 2014, 5, 296. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Siu, K.-L.; Chan, C.-P.; Kok, K.-H.; Woo, P.C.-Y.; Jin, D.-Y. Comparative analysis of the activation of unfolded protein response by spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus HKU1. Cell Biosci. 2014, 4, 3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rothan, H.A.; Kumar, M. Role of endoplasmic reticulum associated proteins in favivirus replication and assembly complexes. Pathogens 2019, 8, 148. [Google Scholar] [CrossRef] [Green Version]
- Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020, 395, 1033–1034. [Google Scholar] [CrossRef] [PubMed]
- Kim, N.-H.; Lee, M.-Y.; Park, S.-J.; Choi, J.-S.; Oh, M.-K.; Kim, I.-S. Auranofn blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology 2007, 122, 607–614. [Google Scholar] [CrossRef] [PubMed]
- Carter, E.D. Oxidation-reduction reactions of metal ions. Environ. Health Perspect. 1995, 103, 17–19. [Google Scholar] [CrossRef]
- Nencioni, L.; Sgarbanti, R.; Amatore, D.; Checconi, P.; Celestino, I.; Limongi, D.; Anticoli, S.; Palamara, A.T.; Garaci, E. Intracellular Redox Signaling as Therapeutic Target for Novel Antiviral Strategy. Curr. Pharm. Des. 2011, 17, 3898–3904. [Google Scholar] [CrossRef]
- Khomich, O.A.; Kochetkov, S.N.; Bartosch, B.; Ivanov, A.V. Redox Biology of Respiratory Viral Infections. Viruses 2018, 10, 392. [Google Scholar] [CrossRef] [Green Version]
- Mahalingam, S.; Meanger, J.; Foster, P.S.; Lidbury, B.A. The viral manipulation of the host cellular and immune envi ronments to enhance propagation and survival: A focus on RNA viruses. J. Leukoc. Biol. 2002, 72, 429–439. [Google Scholar] [CrossRef]
- Gullberg, R.C.; Steel, J.J.; Moon, S.; Soltani, E.; Geiss, B.J. Oxidative stress influences positive strand RNA virus genome synthesis and capping. Virology 2015, 475, 219–229. [Google Scholar] [CrossRef] [Green Version]
- Chen, K.-K.; Minakuchi, M.; Wuputra, K.; Ku, C.-C.; Pan, J.-B.; Kuo, K.-K.; Lin, Y.-C.; Saito, S.; Lin, C.-S.; Yokoyama, K.K. Redox control in the pathophysiology of infuenza virus infection. BMC Microbiol. 2020, 20, 214. [Google Scholar] [CrossRef] [PubMed]
- Vlahos, R.; Sambas, J.; Bozinovski, S.; Broughton, B.R.S.; Drum Mond, G.R.; Selemidis, S. Inhibition of NOX2 oxi dase activity ameliorates infuenza A virus-induced lung infammation. PLoS Pathog. 2011, 7, e1001271. [Google Scholar] [CrossRef] [Green Version]
- Amatore, D.; Sgarbanti, R.; Aquilano, K.; Baldelli, S.; Limongi, D.; Civitelli, L.; Nencioni, L.; Garaci, E.; Ciriolo, M.R.; Palamara, A.T. Influenza virus replication in lung epithelial cells depends on redox-sensitive pathways activated byNOX4-derivedROS. Cell Microbiol. 2014, 17, 131–145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nencioni, L.; De Chiara, G.; Sgarbanti, R.; Amatore, D.; Aquilano, K.; Marcocci, M.E.; Serafino, A.; Torcia, M.; Cozzolino, F.; Ciriolo, M.R.; et al. Bcl-2 Expression and p38MAPK Activity in Cells Infected with Influenza A Virus. J. Biol. Chem. 2009, 284, 16004–16015. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Damiano, S.; Sozio, C.; La Rosa, G.; Santillo, M. NOX-Dependent Signaling Dysregulation in Severe COVID-19: Clues to Effective Treatments. Front. Cell. Infect. Microbiol. 2020, 10, 608435. [Google Scholar] [CrossRef]
- McKenzie, L.K.; Bryant, H.E.; Weinstein, J.A. Transition metal complexes as photosensitisers in one- and two-photon photodynamic therapy. Coord. Chem. Rev. 2019, 379, 2–29. [Google Scholar] [CrossRef] [Green Version]
- Wiehe, A.; O’Brien, J.M.; Senge, M.O. Trends and targets in antiviral phototherapy. Photochem. Photobiol. Sci. 2019, 18, 2565–2612. [Google Scholar] [CrossRef]
- Dai, T.; Huang, Y.-Y.; Hamblin, M.R. Photodynamic therapy for localized infections—State of the Art. Photodiagnosis Photodyn. Ther. 2009, 6, 170–188. [Google Scholar] [CrossRef] [Green Version]
- Ichimura, H.; Yamaguchi, S.; Kojima, A.; Tanaka, T.; Niiya, K.; Takemori, M.; Hasegawa, K.; Nishimura, R. Eradication and reinfection of human papillomavirus after photodynamic therapy for cervical intraepithelial Neoplasia. Int. J. Clin. Oncol. 2003, 8, 322–325. [Google Scholar] [CrossRef]
- Tardivo, J.P.; Del Giglio, A.; Paschoal, L.H.; Baptista, M.S.; Baptista, M.S. New Photodynamic Therapy Protocol to Treat AIDS-Related Kaposi’s Sarcoma. Photomed. Laser Surg. 2006, 24, 528–531. [Google Scholar] [CrossRef]
- Käsermann, F.; Kempf, C. Photodynamic inactivation of enveloped viruses by buckminsterfullerene. Antiviral. Res. 1997, 34, 65–70. [Google Scholar] [CrossRef] [PubMed]
- Bianchi, M.; Benvenuto, D.; Giovanetti, M.; Angeletti, S.; Ciccozzi, M.; Pascarella, S. Sars-CoV-2 envelope and mem brane proteins: Structural diferences linked to virus char acteristics? Biomed. Res. Int. 2020, 2020, e4389089. [Google Scholar] [CrossRef]
- Allison, R.R.; Moghissi, K. Photodynamic therapy (PDT): PDT mechanisms. Clin. Endosc. 2013, 46, 24–29. [Google Scholar] [CrossRef] [PubMed]
- Svyatchenko, V.A.; Nikonov, S.D.; Mayorov, A.P.; Gelfond, M.L.; Loktev, V.B. Antiviral photodynamic therapy: Inactivation and inhibition of SARS-CoV-2 in vitro using methylene blue and radachlorin. Photodiagnosis Photodyn. Ther. 2021, 33, 102112. [Google Scholar] [CrossRef] [PubMed]
- Wu, M.-Y.; Gu, M.; Leung, J.-K.; Li, X.; Yuan, Y.; Shen, C.; Wang, L.; Zhao, E.; Chen, S. A Membrane-Targeting Photosensitizer with Aggregation-Induced Emission Characteristics for Highly Efficient Photodynamic Combat of Human Coronaviruses. Small 2021, 17, 2101770. [Google Scholar] [CrossRef] [PubMed]
- Keil, S.D.; Bowen, R.; Marschner, S. Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. Transfusion 2016, 56, 2948–2952. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ruane, P.H.; Edrich, R.; Gampp, D.; Keil, S.D.; Leonard, R.L.; Goodrich, R.P. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004, 44, 877–885. [Google Scholar] [CrossRef]
- Blanco, K.C.; Inada, N.M.; Carbinatto, F.M.; Giusti, A.L.; Bagnato, V.S. Treatment of recurrent pharyngotonsillitis by photodynamic therapy. Photodiagnosis Photodyn. Ther. 2017, 18, 138–139. [Google Scholar] [CrossRef]
- Kassab, G.; Gerald, M.C.; Inada, N.M.; Achilles, A.E.; Guerra, V.G.; Bagnato, V.S. Nebulization as a tool for photosen sitizer de-livery to the respiratory tract. J. Biophoton. 2019, 12, e201800189. [Google Scholar] [CrossRef]
- Dias, L.D.; Blanco, K.C.; Bagnato, V.S. COVID-19: Beyond the virus. The use of photodynamic therapy for the treat ment of infections in the respiratory tract. Photodiagnosis Photodyn. Ther. 2020, 31, 101804. [Google Scholar] [CrossRef]
- Moghissi, K.; Dixon, K.; Gibbins, S. Does PDT have potential in treating COVID 19 patients? Photodiagnosis Photodyn. Ther. 2020, 31, 101889. [Google Scholar] [CrossRef]
- Ivan Lozada, M.; Daniela Torres, L.; Maria Bolaño, R.; Luis Moscote, S. High mutation rate in SARS-CoV-2: Will it hit us the same way forever? J. Infect. Dis. Epidemiol. 2020, 6, 371–384. [Google Scholar] [CrossRef]
- Lemire, J.A.; Harrison, J.J.; Turner, R.J. Antimicrobial activity of metals: Mechanisms, molecular targets and applications. Nat. Rev. Microbiol. 2013, 11, 371–384. [Google Scholar] [CrossRef] [PubMed]
- Barry, N.P.E.; Sadler, P.J. Exploration of the medical periodic table: Towards new targets. Chem. Commun. 2013, 49, 5106–5131. [Google Scholar] [CrossRef] [Green Version]
- Johnstone, T.C.; Suntharalingam, K.; Lippard, S.J. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem. Rev. 2016, 116, 3436–3486. [Google Scholar] [CrossRef] [Green Version]
- Lengfelder, E.; Hofmann, W.-K.; Nowak, A.D. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia 2011, 26, 433–442. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Metal-Complex | Virus | Application | Reference |
---|---|---|---|
Au(I)–2,3,4,6-tetra-O-acetyl-l-thio-β-d-glycol-pyranoses-S-(triethyl-phosphine) (AF) | HIV-1, SARS-CoV-2 | Antiviral therapy | [23,80,81] |
Au(I)–Aurothiomalate | HIV-1 | Antiviral therapy | [80] |
Au(I)–Aurothioglucose | HIV-1 | Antiviral therapy | [82] |
Ga(III)–Curcumin | HSV-1 | Antiviral therapy | [83] |
Co(III)–Doxovir | HSV-1 | Antiviral therapy | [84] |
Cu(II) Ni(II) Co(II) Zn(II) Cr(III)–Tenoxicam, valine | Infectious Bovine Rhinotracheitis (IBR) | Vaccine therapy | [71] |
Cu(II) Ni(II) Co(II) Zn(II) Cr(III)–5,5-[3-diyl)]bis(quinolin-8-ole) | Bovine respiratory syncytial (BRS) | Vaccine therapy | [73] |
AuNPs–FMD virus-like particles (VLPs) | Foot-and-mouth disease (FMD) | Vaccine therapy | [79] |
AuNPs–West Nile Virus (WNV) envelope (E) protein | West Nile Virus (WNV) | Vaccine therapy | [85] |
AuNPs–STG antigen | Enteropathogenic coronavirus of transmissible porcine gastroenteritis (STG) | Vaccine therapy | [86] |
AuNPs–PEG-S461-493 | SARS-CoV-2 | Vaccine therapy | [87] |
AuNPs–Protein S | SARS-CoV-2 | Vaccine therapy | [88] |
AuNPs–Raltegravir (RAL) | HIV | Drug delivery | [89] |
AuNPs–FMD virus protein | FMD | Drug delivery | [90] |
AuNPs–Stavudine | HIV | Drug delivery | [91] |
AuNPs–siRNA | DENV | Drug delivery | [92] |
Fe(III)–NanoMOFs [59] | HIV | Drug delivery | [93] |
Fe(III)–Tenoxicam, valine | IBR | Vaccine therapy | [71] |
NiNPs–His-Tat cationic antigen | HIV | Drug delivery | [94] |
AgNPs–Spike proteins | SARS-CoV-2 | Drug delivery | [95] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gopal, J.; Muthu, M.; Sivanesan, I. A Comprehensive Survey on the Expediated Anti-COVID-19 Options Enabled by Metal Complexes—Tasks and Trials. Molecules 2023, 28, 3354. https://doi.org/10.3390/molecules28083354
Gopal J, Muthu M, Sivanesan I. A Comprehensive Survey on the Expediated Anti-COVID-19 Options Enabled by Metal Complexes—Tasks and Trials. Molecules. 2023; 28(8):3354. https://doi.org/10.3390/molecules28083354
Chicago/Turabian StyleGopal, Judy, Manikandan Muthu, and Iyyakkannu Sivanesan. 2023. "A Comprehensive Survey on the Expediated Anti-COVID-19 Options Enabled by Metal Complexes—Tasks and Trials" Molecules 28, no. 8: 3354. https://doi.org/10.3390/molecules28083354